What caused sudden sight loss in Wegovy users?

Researchers' findings and clinical implications

A new study identified a notably higher rate of sudden vision loss among patients using one formulation of semaglutide-based therapy compared with another. Researchers reported that users of the higher‑dose weight‑loss formulation experienced nearly five times the risk of an abrupt reduction in vision compared with users of the diabetes formulation. Authors described the events as likely related to ischemic injury — an "eye stroke" that reduces blood flow to the optic nerve — and suggested the active ingredient, semaglutide, as the plausible cause.

Why this matters

Semaglutide is the active drug in both diabetes and obesity products and has been prescribed widely as use of GLP‑1 agents has ballooned. The finding raises urgent questions about dose, formulation, and which patients may be vulnerable to rare but severe ocular complications. Because sudden vision loss can be permanent, timely recognition and reporting are critical to patient outcomes and to public health surveillance.

What clinicians and patients should know

• Watch for warning signs: sudden blurring, loss of part of the visual field, or a dark curtain across vision warrant immediate medical evaluation.
• Risk assessment: it is still unclear which underlying conditions — such as vascular disease or preexisting eye problems — increase susceptibility.
• Reporting and follow‑up: suspected cases should be documented and reported so regulators can better quantify the risk and issue guidance.

The study highlights the need for more data and for clinicians to discuss rare but serious risks with patients when choosing among GLP‑1 treatment options.